Home Cart Sign in  
Chemical Structure| 91037-65-9 Chemical Structure| 91037-65-9

Structure of H-Arg-Gly-Asp-Ser-OH
CAS No.: 91037-65-9

Chemical Structure| 91037-65-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Arg-Gly-Asp-Ser (RGDS) is a synthetic integrin antagonist, a specific peptide motif through which extracellular matrix (ECM) components interact with integrin and can modify the behavior of cells.

Synonyms: RGDS peptide; Fibronectin tetrapeptide; H-Arg-Gly-Asp-Ser-OH

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of H-Arg-Gly-Asp-Ser-OH

CAS No. :91037-65-9
Formula : C15H27N7O8
M.W : 433.42
SMILES Code : O=C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(O)=O)=O)=O)[C@H](CCCNC(N)=N)N
Synonyms :
RGDS peptide; Fibronectin tetrapeptide; H-Arg-Gly-Asp-Ser-OH
MDL No. :MFCD00076452
InChI Key :NNRFRJQMBSBXGO-CIUDSAMLSA-N
Pubchem ID :107775

Safety of H-Arg-Gly-Asp-Ser-OH

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of H-Arg-Gly-Asp-Ser-OH

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-MEL-110 cells 500 μg/ml 24 h To study the internalization of RGDS in SK-MEL-110 cells. FACS analysis showed that biotinylated RGDS entered about 40% of cells within 24 hours, while the control peptide RGES internalized at a slower rate (about 30% of cells). Mol Cancer. 2010 Apr 22;9:84
SK-MEL-110 cells 500 μg/ml 48 h To investigate the effect of RGDS on proliferation and apoptosis in SK-MEL-110 cells. Results showed that RGDS significantly inhibited FGF-2-induced proliferation (46 ± 16% inhibition, p < 0.005) and increased the proportion of sub-G1 phase cells (from 3% to 13.2%), indicating anti-proliferative and pro-apoptotic effects. Mol Cancer. 2010 Apr 22;9:84
platelets 300 μM 30 min Inhibition of platelet interactions with adsorbed albumin, results showed RGDS peptide significantly inhibited platelet adhesion Biomaterials. 2010 Feb;31(6):1036-44
Human umbilical vein endothelial cells 250 μg/mL 24 h To evaluate the effect of RGDS peptide on the expression of EndMT markers Snail1 and N-cadherin in HUVECs, results showed that RGDS peptide partially downregulated the expression of these markers. iScience. 2022 Nov 19;25(12):105642.
CHO cells 1 mM The RGDS peptide virtually abolished the binding of CHO-PODXL cells to platelets Cell Mol Life Sci. 2007 Nov;64(22):2965-74

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Ccm1ECKO mouse model Intraperitoneal injection 5 mg/kg From P5–P7 daily and P9–P13 every alternate day To evaluate the effect of RGDS peptide on the development of CCM lesions, results showed that RGDS peptide reduced the lesion area in the cerebella and retinas of Ccm1ECKO mice. iScience. 2022 Nov 19;25(12):105642.
BALB/C mice LPS-induced acute lung injury model Intraperitoneal injection 1, 2.5, or 5 mg/kg Single dose, 1 hour before or 2 hours after LPS treatment RGDS inhibited LPS-induced increases in neutrophil and macrophage numbers, total protein levels, TNF-α and MIP-2 levels, and MMP-9 activity Respir Res. 2009 Mar 9;10(1):18

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.54mL

2.31mL

1.15mL

23.07mL

4.61mL

2.31mL

References

 

Historical Records

Categories